Beta Bionics (BBNX) CMO sells 1,025 shares to cover RSU tax withholding

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 1,025 shares of Common Stock at an average price of $29.3359 per share on December 2, 2025. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 178,071 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Steven Jon

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/02/2025		S(1)		1,025	D	$29.3359	178,071	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

	/s/ Stephen Feider, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beta Bionics (BBNX) report for Russell Steven Jon?

Beta Bionics reported that Chief Medical Officer Russell Steven Jon sold 1,025 shares of Common Stock. The sale occurred on December 2, 2025, and was executed as an open-market transaction, according to the Form 4 insider trading report.

At what price were the Beta Bionics (BBNX) shares sold in this Form 4?

The 1,025 Beta Bionics shares were sold at an average price of $29.3359 per share. This price reflects the consideration received in the open-market sale disclosed in the Form 4 filed for Chief Medical Officer Russell Steven Jon.

Why did Beta Bionics executive Russell Steven Jon sell shares according to the filing?

The filing states the shares were sold to cover tax withholding obligations from the vesting of restricted stock units. This indicates the sale was related to compensation and tax requirements rather than a discretionary open-market trade for portfolio or valuation reasons.

How many Beta Bionics (BBNX) shares does Russell Steven Jon hold after the transaction?

After the reported sale, Russell Steven Jon directly holds 178,071 shares of Beta Bionics Common Stock. This post-transaction balance is disclosed in the Form 4 and shows his remaining equity position following the tax-related share sale.

What role does Russell Steven Jon hold at Beta Bionics (BBNX)?

Russell Steven Jon serves as Chief Medical Officer at Beta Bionics. His position as an officer makes him a reporting person for insider transactions, requiring disclosure of equity trades such as the tax-related share sale reported in this Form 4 filing.

Was the Beta Bionics (BBNX) insider sale linked to derivative exercises or options?

The Form 4 describes the transaction as a sale of Common Stock and notes the shares were sold to cover tax withholding from vesting restricted stock units. The derivativeSummary section shows no derivative transactions, indicating no option or similar derivative exercise was reported here.